Boehringer Ingelheim starts a Phase 2 trial of a Gubra-originated triple agonist

Gubra, a Danish peptide-drug-discovery company, announced on July 16, 2026, that its partner Boehringer Ingelheim had initiated a Phase 2 clinical trial of a triple receptor agonist for people living with overweight and obesity ^[1]. The announcement appears in Gubra's list of company news releases, but the source material available does not include the trial's design, dosing, participant numbers, or specific efficacy or safety endpoints ^[1].

Gubra describes itself as a "disease-agnostic techbio company" founded in 2008 in Denmark and listed on Nasdaq Copenhagen, with roughly 300 employees and 2025 revenue of about 2.6 billion Danish kroner, or around $400 million ^[1]. The company's business model relies on licensing early-stage peptide candidates to larger pharmaceutical partners in exchange for milestone payments and royalties, a structure it has also used with AbbVie ^[1].

For comparison, Gubra's other lead partnered asset, ABBV-295, is a long-acting amylin analog licensed to AbbVie in March 2025 in a deal worth up to $1.875 billion in potential milestones plus tiered royalties ^[1]. In Phase 1 multiple-ascending-dose testing reported in March 2026, ABBV-295 produced dose-dependent weight loss of 7.75% to 9.79% at 12 weeks in weekly-dosing groups, versus about 0.26% for placebo, with mostly mild gastrointestinal side effects and no serious adverse events reported among 76 participants ^[1]. That drug works differently than GLP-1 medicines, acting on amylin and calcitonin receptors rather than the incretin pathway used by semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) ^[1].

It is important not to confuse the two programs. The triple receptor agonist now in Phase 2 with Boehringer Ingelheim is a separate molecule from ABBV-295, and the sources reviewed here do not specify which receptors it targets, what results were seen in earlier-stage testing, or what the summary description of "strong late-2025 clinical results" refers to in terms of specific numbers. That detail is not yet known from the material available ^[1].

Why it matters for patients

A new obesity drug entering Phase 2 testing means it is still years away from being available by prescription, if it reaches the market at all. Phase 2 trials typically test a range of doses in a larger group of patients to look more closely at effectiveness and side effects before a company decides whether to move into the larger, longer Phase 3 trials required for regulatory approval.

For people currently using or considering GLP-1 medicines such as semaglutide or tirzepatide, this development signals that competition in the obesity-drug field continues to grow, with multiple companies pursuing drugs that combine several hormone-receptor targets in a single molecule. More competition and more mechanisms in testing could eventually mean more choices for patients, including options with different side-effect profiles or dosing schedules. But none of that is guaranteed, and nothing in the available sources describes how this specific triple agonist might compare to existing approved drugs in terms of weight loss, tolerability, or safety ^[1].

What happens next

The Phase 2 trial was announced as initiated on July 16, 2026 ^[1]. Gubra's public disclosures note that the company received a milestone payment from AbbVie following a separate Phase 2 initiation for ABBV-295, suggesting similar milestone-based arrangements may apply to the Boehringer Ingelheim partnership, though this is not confirmed for the triple agonist specifically ^[1]. No timeline for Phase 2 completion, interim data readouts, or potential Phase 3 initiation for the triple receptor agonist appears in the sources reviewed. Readers should expect that meaningful efficacy and safety data, if released, would likely take one to two years given typical Phase 2 trial durations, though this estimate is not stated directly in the available material.